Anti-inflammatory agent 117

Anti-inflammatory agent 117 是一种具有口服活性的抗炎剂和 c-Kit 激酶抑制剂(IC50 为 15.2 μM),它通过阻断 NF-κB 信号通路并抑制 IL-6 的释放,在急性肺损伤、脓毒症和溃疡性结肠炎的小鼠模型中表现出抗炎作用,可用于这些疾病的相关研究。
Anti-inflammatory agent 117
产品编号: MS-T80966 分子式: C30H25N5O4S 分子量: 551.62
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Anti-inflammatory agent 117 是一种具有口服活性的抗炎剂和 c-Kit 激酶抑制剂(IC50 为 15.2 μM),它通过阻断 NF-κB 信号通路并抑制 IL-6 的释放,在急性肺损伤、脓毒症和溃疡性结肠炎的小鼠模型中表现出抗炎作用,可用于这些疾病的相关研究。

生物实验数据

生物活性 Anti-inflammatory agent 117 is an orally active anti-inflammatory agent and c-Kit kinase inhibitor with an IC50 of 15.2 μM that blocks the NF-κB signaling pathway and inhibits IL-6 release, exhibits anti-inflammatory effects in mouse models of acute lung injury, sepsis, and ulcerative colitis, and can be used for research related to acute lung injury, sepsis, and ulcerative colitis.
IC50 & Target

IL-6

 

体外研究
(In Vitro)

Anti-inflammatory agent 117 (Compound z18) (10 μM;预处理 30 分钟,LPS 刺激 24 h) 可强效抑制 LPS 刺激的 J774A.1 巨噬细胞中 IL-6 的释放,在 10 μM 浓度下抑制率达 78.55%。
Anti-inflammatory agent 117 (10 μM; 24 h) 在 J774A.1 巨噬细胞中显示出低细胞毒性。
Anti-inflammatory agent 117 (10 μM; 2 h) 可通过维持 IκBα 水平并降低 p-p65 水平,抑制 LPS 刺激的 J774A.1 巨噬细胞中 NF-κB 信号通路的激活。
Anti-inflammatory agent 117 (10-100000 nM) 在无细胞生化实验中可中度抑制 c-Kit 激酶活性,其 IC50 为 15.2 μM。
Anti-inflammatory agent 117 (37°C 条件下处理 2-8 h) 在 37°C 条件下于大鼠血清、模拟胃液及无酶模拟肠液中表现出良好的 8 小时稳定性,在含酶模拟肠液中仅发生中度降解 (8 h 后残留浓度约 55%)。

体内研究
(In Vivo)

Anti-inflammatory agent 117 (20 mg/kg;口服) 可通过降低肺水肿、炎症细胞浸润以及蛋白和 mRNA 水平的炎症细胞因子产生,显著减轻小鼠体内 LPS 诱导的急性肺损伤。
Anti-inflammatory agent 117 (20 mg/kg;口服) 可改善 LPS 诱导脓毒症小鼠的生存结局并减轻其体重下降。
Anti-inflammatory agent 117 (20 mg/kg;口服;每日一次;连续 10 天) 可通过减轻体重下降、结肠缩短、脾肿大、全身炎症及组织病理损伤,显著改善 DSS 诱导的小鼠溃疡性结肠炎。

Animal Model: C57BL/6 (male, 19-23 g, intratracheal LPS-induced acute lung injury)
Dosage: 20 mg/kg
Administration: p.o.; single dose 30 minutes prior to LPS challenge
Result: Significantly reduced the lung wet/dry ratio compared to the LPS group.
Significantly decreased total protein concentration and total cell count in BALF compared to the LPS group.
Significantly reduced BALF levels of IL-6 and TNF-α compared to the LPS group.
Significantly reduced serum levels of IL-6 and TNF-α compared to the LPS group.
Reduced lung tissue neutrophil and macrophage infiltration, attenuated pulmonary edema, congestion, and alveolar wall thickening.
Significantly lowered lung tissue mRNA levels of IL-6, TNF-α, and IL-1β compared to the LPS group.
Animal Model: C57BL/6 (intraperitoneal LPS-induced sepsis)
Dosage: 20 mg/kg
Administration: p.o.; single dose 1 hour prior to LPS challenge
Result: Delayed mortality (deaths occurring between 36 and 60 hours) with a subset surviving until the end of the 10-day observation period, while all mice in the LPS group died between 24 and 36 hours.
Slowed the rate of weight loss in septic mice, with body weight stabilizing after 60 hours.
Animal Model: C57BL/6 (2.5% DSS-induced ulcerative colitis)
Dosage: 20 mg/kg
Administration: p.o.; daily; 10 days
Result: Reduced DSS-induced body weight loss, partially restoring weight after DSS withdrawal.
Increased colon length to 7.6 cm (compared to 5.8 cm in the DSS model group).
Reduced spleen weight to near normal control levels.
Maintained a significantly lower DAI score throughout the experimental period compared to the DSS model group.
Significantly reduced serum IL-6 levels compared to the DSS model group.
Attenuated histopathological damage in colon (reduced goblet cell loss, crypt necrosis, and mucosal destruction) and spleen (reduced white pulp fusion and red pulp macrophage infiltration), as well as suppressed inflammatory cell infiltration in colon tissue.

化学信息

分子量 551.62
分子式 C30H25N5O4S

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础